Steve Case and the Rise of the Rest team will be visiting Harrisburg-Lancaster-York for their next official tour. Eight finalists are selected in each city for a pitch competition and the winner will receive a $100,000 personal investment from Steve Case! The Harrisburg-Lancaster-York pitch competition will occur on Tuesday, October 10.
LLANTRISANT, Wales, June 21, 2017 /PRNewswire/ —
Purolite Life Sciences, a leading provider of specialty resins, and ChromaTan Corporation, a single-use chromatography solutions provider, today announce a successful collaboration for the development and commercialisation of a custom-designed, novel Protein A resin bead designed specifically to address the needs of continuous manufacturing.
The new resin bead exploits the capabilities of ChromaTan’s Continuous Countercurrent Tangential Chromatography (CCTC) system – the first resin-based, column-free chromatography system – to provide up to 15x increases in productivity for Protein A capture, intermediate and polishing steps.
Micro Interventional Devices, Inc. Wins CRT 2017’s “Top Cardiovascular Innovation Award” for MIA(TM), Minimally Invasive Annuloplasty Technology
World’s first annuloplasty system for mitral and tricuspid repair incorporating proprietary PolyCor(TM) and MyoLast(TM) technologies.
Newtown, PA – March 2, 2017 – Micro Interventional Devices, Inc™ (MID), is pleased to announce that it is the recipient of the CRT 2017 “Top Cardiovascular Innovation Award” for the company’s MIA technology. The award was presented to Michael Whitman, MID’s Founder, President and CEO, during the 20th annual CRT meeting on Tuesday, February 21st. [Read more…]
Tests can lead to early identification of Alzheimer’s Disease
Bethlehem, PA–(BUSINESS WIRE)–January 18, 2017– Saladax Biomedical, Inc., a privately held company focused on precision in-vitro diagnostic tests, announced today that it has signed an agreement to license diagnostic tests for Alzheimer’s disease (AD) to Siemens Healthineers. Saladax’s tests identify the amyloid beta 1-42 and tau biomarkers in cerebrospinal fluid (CSF) which are known and accepted biomarkers for AD. [Read more…]